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Synopsis
There is epidemiological evidence that a substantial number of adults suffer YOD. The diversity
of types and syndromes makes recognition and diagnosis difficult. An algorithmic approach to
interpreting clinical data, informed by clinical epidemiology, integrates data pertaining to defining
syndromes, and their chronology and tempo, family history, and other neuropsychiatric features
and neurological signs, to reach a preliminary diagnosis and direct diagnostic tests and their
interpretation. Screening for YOD in the psychiatric context is a rational process in which
vigilance is combined with careful searches for ‘red flags’ that signal a neurodegenerative
etiology.
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Young-onset presentations of dementia are increasingly recognized as important causes of
midlife morbidity and mortality. Young-onset dementia (YOD), typically defined as
dementia arising before the age of 65, is also referred to as early-onset dementia (and in
older times it was commonly known as presenile dementia). This age threshold, albeit
socially determined and arbitrary, has proved useful for practice innovations and for
research. It has, for example, provided a framework for distinguishing young-onset
dementias from the more common late-life occurrences, which serves important differences
in etiology, phenotypes, handicaps, psychosocial difficulties and, ultimately, clinical care.
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Whereas late-life dementias are, with the exception of those stemming from cerebrovascular
disease, generally neurodegenerative, the YOD are more heterogeneous. Although most
YOD are neurodegenerative, many cases arise from genetic, infectious, autoimmune,
vascular, nutritional, and metabolic etiologies.
YOD is overshadowed in the clinical and public consciousness by the higher prevalence of
dementia in later life – and the perception that dementia is a condition of the elderly. Owing
to this low consciousness, and physicians’ lack of familiarity with the various conditions
from which YOD arises, the diagnosis is frequently missed or late. For example, one study
showed an average time to diagnosis of 4.5 years, which was 1.6 years longer than for the
late onset group in that study1.
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Knowledge amongst clinicians, and the public, of the clinical and demographic
characteristics of YOD will facilitate recognition and accurate diagnosis, and thereby
prompt and effective care. Effective care includes treatment of the neuropsychiatric facets of
these disorders, and management of the psychosocial needs of the individuals and families
suffering these conditions. YOD frequently manifest neuropsychiatric phenomena alongside
impairments of cognitive functions, often presenting with abnormalities of affect,
temperament, judgment, dispositions and self-control, perception, ideation, and subsistence
behaviors (feeding, elimination, sexual expression, and sleep). The psychosocial problems
arising from these conditions include conflict, financial strain (since the patient may be a
primary breadwinner or the caregiver of children), emotional stress on spouses (and other
relatives) who provide care, work, and parenting, and suffer social disconnection due to
distraction and isolation 2. Children of individuals who suffer young-onset dementias also
suffer adaptation-related stresses 3,4. Thus YOD is topical for psychiatry because of the
phenotypes firstly, the psychosocial dimensions of the suffering too, and the skillset of the
specialty. Psychiatrists, by virtue of their multidimensional training and professional
orientation, have the tools to treat the illness, manage the problems, and direct the
rehabilitation.
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This paper, like others in this issue, provides an introduction to aspects of YOD that are
important for psychiatric practice. Here we discuss the clinical epidemiology of the
neurodegenerative forms of YOD, including the pertinence of this to clinical work. We point
out the demographic and phenotypic attributes of YOD that provide clues aiding the clinical
recognition of the various etiologic types. Screening and measurement are also covered. The
aim is to provide psychiatrists and other mental health professionals with a basic
understanding that, it is hoped, will enhance their capacity to identify the cases, treat and
rehabilitate them, and advocate for policies that meet their needs.
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Method
A literature search for studies of the epidemiology of young onset dementia used the
PubMed and Google Scholar databases, searching for full text papers written in the English
language. The search terms are: “Young Onset Dementia” or “Early Onset Dementia” in
combinations with “prevalence” or “incidence” or “survival” or “mortality”. We reviewed
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the references of the papers we found for additional sources. We also scoured sources with
which we were already familiar, particularly topical reviews and white papers.
Frequency and distribution
Estimates of the frequency of YOD are scarce; what data are available derive from
catchment area or specialty clinic samples, using for case identification surveys of local
clinics and hospitals, medical record review, disease registries, and passive surveillance of
defined geographical regions. Direct ascertainment from the population is difficult, due to
the rarity and diversity of YOD conditions, their diagnostic complexity (which demands
expertise), and the public's lack of familiarity with these conditions (which makes surveys
difficult to design).

Author Manuscript

The proportions of specialist clinic (or memory clinic) patients who suffer YOD are shown
in Table 1. These data indicate that the frequency of YOD in specialist clinics ranges from
7.3-44% 5-11, these estimates reflecting differences between regions and centers in the
clinical focus, local practices, referral base, and sampling methods. For example, the study
conducted in Greece, which reports the highest frequency, received referrals mainly from
academic psychiatrists and neurologists – which may have resulted in a case selection
favoring atypical forms of dementia (and younger cases than the typical memory clinic).

Author Manuscript

The prevalence of all-cause YOD in communities (see Table 2). These studies, which
typically identify cases in the catchment area of a specialist center or network, show
prevalence rates ranging 42.3–68.2 per 100,000 12-16. Variability results from differences
between case mix (see Table 3), and in the sampling methods (for example, see the
differences in sample age ranges shown in Table 2). The incidence of all-cause YOD, based
on the three studies conducted to date, is 11-13.4 per 100,000 17-19.
Etiology
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The case mix in prevalence studies of YOD is broad, comprising Alzheimer disease (AD),
frontotemporal dementia (FTD), vascular dementia (VaD), Huntington disease (HD),
Parkinson disease (PDD) and dementia with Lewy bodies (DLB), alcohol-related dementia
(ARD), and traumatic brain injury (TBI) 5,6,8-10,12,13,15,16,20,21. AD and FTD are the most
frequent neurodegenerative causes of YOD (see Table 3 for frequencies derived from
prevalence studies). In the United States, it has been estimated that 200,000 suffer youngonset AD 22 and between 12,000 and 18,000 suffer young-onset FTD 23. Cerebrovascular
disease and stroke are important causes of YOD in Japan 13. Neurodegenerative causes of
YOD predominate beyond age 3521, and it has been estimated that they comprise 30% of all
YOD 24. TBI, ARD, and HIV-Associated Neurocognitive Disorder are mainly seen among
the poor living in inner cities 6.
Risk factors
Hereditary transmission is the most established risk factor for neurodegenerative forms of
YOD. Hereditary forms of AD and FTD arises arise from autosomal dominant mutations in
several genetic loci (see Table 4, which also shows data for Huntington disease and prion
disease). Mutations in specific genetic loci are often associated with phenotypic variants, as
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shown in Table 4. For example, the mutation in the C9ORF72 gene gives rises to a
phenotype of FTD with amyotrophic lateral sclerosis (FTD-ALS), which is often also
heralded or complicated by psychosis.
Repeated concussive head traumas, typically sustained in sports such as boxing, American
football, and ice hockey, are now known to cause chronic traumatic encephalopathy, a
neurodegenerative dementia 25 characterized by widespread cortical and subcortical
tauopathy. Low cognition, alcohol abuse, high blood pressure, stroke, depression, and
neuroleptic use in youth, have been linked to YOD in midlife in one study 26. Another study
has shown association between YOD and cardiovascular disease – stroke, TIA, chronic
kidney disease, and hypertension 27.
These findings suggest opportunities for primary prevention 28

Author Manuscript

Survival
Life expectancy after diagnosis varies widely in YOD, according to the etiologic type, but
appears to be shorter in general than for late-onset dementia 29. It has been estimated that
median survival from diagnosis for YOD (derived from a study in sampling mainly AD and
VaD cases) is 6 years 30. Median survival from diagnosis of FTD is about 7-13 years in
clinic cohorts and 6-8 years in neuropathological series 31. Survival is much shorter in FTDALS, showing median survival of 27 months 32. Survival in prion disease cases is
comparable to that in FTD-ALS, although some cases survive up to 2-3 years 33.
Clinical and diagnostic considerations
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The diagnosis of YOD is frequently missed, because of the wide diversity of types, a
predominance of non-memory and neuropsychiatric features over cognitive deficits in many,
and (relative to late-onset dementia) a high frequency of syndromes that are defined by
motor dysfunctions such as parkinsonism, apraxia, and ataxia.
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When certain diagnostic principles are followed, which derive from a clinical epidemiology
that defines syndromes according to their signal phenomena, the differential diagnosis can
be sharply narrowed. This entails an algorithmic approach, not as a sequence of procedures,
but in the sense of a methodical consideration of the clinical data. The key data elements are
the cluster of cognitive, neuropsychiatric and motor symptoms and signs defining a
syndrome, their chronology and tempo, and family history (particularly of neuropsychiatric
and neurologic illnesses). These data guide what diagnostic procedures are selected –
psychometric measurements, serological and biochemical assays, brain imaging, and
genotyping – and facilitates their interpretation. This approach is illustrated in Figure 1,
which presents an algorithmic approach for using syndrome type (defined from the most
salient symptoms and signs) to progressively narrow the differential diagnosis.
Differential diagnosis as a function of defined syndromes
The first branch point in our algorithm (in Figure 1) involves weighing the chronology and
tempo of the illness. An insidious, ingravescent course is typical of most neurodegenerative
disorders, including AD, FTD, HD, and DLB, and is also true of some presentations of
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vascular dementia 34. An abrupt and rapid development can arise from some
neurodegenerative states, such as prion disease and FTD-ALS, but is frequently the
manifestation of non-neurodegenerative processes such as stroke, autoimmune
encephalitides, and CNS infections. Prion and other rapidly progressing dementias are
covered in another paper in this issue. As noted earlier, neurodegenerative YOD can
manifest in a variety of ways, as cognitive syndromes, neuropsychiatric states, and motor
syndromes that are accompanied by cognitive and/or behavioral features.

Author Manuscript
Author Manuscript
Author Manuscript

A. Syndromes that are primarily cognitive (i.e., cognitive > behavioral in
Figure 1)—cognitive presentations predominate in YOD, in part because AD is the most
common type. Impaired episodic memory is the typical presenting feature of AD, in youngand late-onset cases. In this sense, young-onset AD resembles the classic late-onset
phenotype in its presenting features and clinical evolution. However, non-amnesic
phenotypes are common in YOD – i.e., syndromes in which visuoperceptual impairments,
aphasia, or ideomotor apraxias predominate 35, and those in which the syndrome is defined
by neuropsychiatric states (such as abnormal conduct, affective disturbance, and psychosis),
or by motor dysfunctions (such as parkinsonism, ataxia, apraxia, or paresis). Posterior
cortical atrophy is one such syndrome, where the highlight is progressive visual or
visuospatial impairment in absence of ophthalmological impairment. Classically, three
subtypes have been recognized – a biparietal syndrome (featuring limb and oculomotor
apraxia, visuospatial disturbance, simultagnosia, optic ataxia, and agraphia), an occipital
syndrome (featuring alexia, apperceptive agnosia and prosopagnosia), and a visual variant
(manifesting as primary visual failure and impairment of basic perceptual abilities).
Logopenic progressive aphasia (PLA), an aphasia variant of AD, is more common in
younger AD patients. It features impaired word retrieval (in spontaneous speech and
confrontation naming), severe sentence repetition deficits, and phonological errors in
spontaneous speech. Another well recognized aphasia syndrome, semantic dementia, is a
variant of FTD. Semantic dementia (SD) is a syndrome of progressive loss of word and
object knowledge that, in its early stages, presents with dysnomia and ‘forgetting’ of words
and objects, along with regularization errors in reading and writing. In later stages, the
patient's speech becomes progressively vacuous (i.e., empty), even though articulation,
syntax, and grammar are not impaired. Speech production, whether spontaneous or in
repetition tasks, is unimpaired in SD. Progressive non-fluent aphasia, PNFA, is another
widely recognized aphasia syndrome of FTD. It is a state in which there is progressive loss
of speech fluency and articulation. This manifests clinically as hesitant, effortful, halting
speech, with errors of grammar. Many cases of PNFA are accompanied by speech apraxia,
recognized can be recognized from the sound distortions in speech which arise from
articulatory dyscontrol. Impaired comprehension of complex sentences is also observed
(since a key aspect of the condition is impaired processing of the syntactical aspects of
language). The patients eventually become mute. A formal classification of the aphasia
syndromes has been developed 36 and widely adopted.
As noted earlier, a small number of non-amnesic young-onset AD cases manifest a
progressive ideomotor and limb apraxia. These have are designated progressive ideomotor
apraxia.
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B. Syndromes that are primarily neuropsychiatric (i.e., behavioral>cognitive)
—Abnormalities of conduct define the neuropsychiatric variant of FTD (widely known as
behavioral variant frontotemporal dementia, bvFTD). This bvFTD syndrome and the
language syndromes discussed earlier are the canonical FTD states 37. This condition
manifests as a progressive coarsening of temperament, judgment, conduct, and social skills,
and derangements of volition. Formal diagnostic criteria have been developed 38. It is not
uncommon for bvFTD to be accompanied by a progressive spastic paresis, in which case the
condition is known as FTD-ALS. Parkinsonism can also accompany it, but the condition is
primarily a derangement of behavior.

Author Manuscript
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C. Syndromes defined by motor dysfunction (i.e., motor disorder > cognitive/
behavioral)—these syndromes are defined by motor dysfunction – parkinsonism, motor
apraxia, dyscontrol, spastic paresis, abnormalities of posture and gait, chorea, and/or ataxia.
DLB and PDD overlap in their clinical and pathological features, differing primary in the
order of emergence of parkinsonism and dementia, and the in symmetry of the former
(lateral asymmetry is typical of Parkinson disease). In DLB, dementia precedes
parkinsonism, or both states emerge simultaneously (or in very close temporal proximity),
Generally in PDD, dementia does not appear in the first decade of the illness, although
formal neuropsychological assessment may uncover subclinical executive dysfunction in
some patients in the early stages. Dementia is a central feature of DLB. Parkinsonism is a
core feature of the syndrome. Dementia arising within versus one year after parkinsonism is
the convention for separating DLB from PDD 39. Rest tremor is uncommon common in
DLB, whereas it is seen in the majority of PDD cases. As noted earlier, lateral asymmetry is
typical of PDD. Axial tendency, and more pronounced masked facies, postural instability
and gait disorder in DLB, are additional features that facilitate distinguishing the two
conditions 39. DLB and PDD show fluctuations of alertness, attention and mentation, and
recurrent formed visual hallucinations. Paranoia and delusions are not uncommon in these
conditions. Chorea and dyskinesias are typical of adult onset HD. Chorea is the most
prominent feature and appears early. Impaired involuntary movements such as
incoordination, bradykinesia and rigidity are mainly seen in earlier onset HD. Executive
dysfunction, behavioral rigidity, irritability, and flighty emotions are also early
features 40,41, but are overshadowed by the dramatic motor phenomena.
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Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) have
overlapping clinical and pathological features. CBD features asymmetric limb apraxia,
akinesia, rigidity, dystonia, along with oral buccal apraxia, dysarticulation of speech (speech
apraxia), and dysarthria. Executive dysfunction, which develops early, is overshadowed by
the motor phenomena. Many cases develop the behavioral and language dysfunctions
associated with FTD during the illness 42. PSP features oculomotor palsy, postural
instability with retropulsion (i.e., a tendency to fall backwards), executive dysfunction,
behavioral dyscontrol, and symmetric parkinsonian features (rigidity, tremor, hypo/
bradykinesia).
Amyotrophic lateral sclerosis (ALS) commonly features cognitive impairments, and is
accompanied by aphasia and FTD syndromes in a subset43. This phenomenon is now known
to be linked to mutation of the C9ORF72 gene 44,45. ALS features progressive limb and/or
Psychiatr Clin North Am. Author manuscript; available in PMC 2016 June 01.
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pharyngeal spasticity, muscle wasting and fasciculations, and paresis (progressing to
paralysis). Many cases manifest emotional dysfunction, characterized by involuntary or hairtrigger laughing and crying (the so called pseudobulbar affect).

Author Manuscript

Most cases of Creutzfeldt-Jakob disease (CJD) are sporadic forms (i.e., sCJD). sCJD is a
rapidly progressive dementia manifesting some combination of ataxia, myoclonus, cortical
blindness, motor dyscontrol, spasticity, incoordination, parkinsonism, and akinetic mutism.
Several atypical forms are recognized: an ataxic CJD in which loss of coordination
predominates; a visuoperceptual variant that culminates in cortical blindness; an
amyotrophic variant featuring progressive spastic paresis and progressive muscle atrophy;
an encephalopathic type featuring rapidly progressive dementia with myoclonus and akinetic
mutism. CJD may also present with a predominance of cognitive impairments (mainly
amnesia, disorientation and apraxia), or as a primary neuropsychiatric state featuring
depression, anxiety, and agitation 46.
Spinocerebellar ataxias are a family of hereditary cerebellar degenerations manifesting
progressive ataxia and incoordination, accompanied by dysarthria and dysphagia. They can
be distinguished from ataxic CJD states by their very gradual evolution, typically spanning a
few decades. Executive dysfunction, cognitive dysmetria, and affective lability can be
observed seen in many cases 47. Dementia is not universal, but severe dysarthria, motor
incoordination, incontinence, and dyscontrol of cognition and affect can mimic a mild
dementia.

Author Manuscript

Vascular dementia (VaD) is not depicted in Figure 1; it is not neurodegenerative and often
arises from overt stroke, in which case the diagnosis is straightforward. The clinical picture
is variable, as it depends on the mechanism and distribution of the cerebrovascular disease
underlying its development. Though VaD is common after stroke, it may follow relatively
small infarcts in strategic locations, or arise from chronic cerebrovascular insufficiency 34.
Thus VaD may arise as a sudden and catastrophic crippling of cognitive, mental, and motor
functions following hemorrhagic stroke; as the classical stepwise decline in cognition
accompanied by behavioral and motor phenomena; or as a hemiplegic or hemiparetic state
with focal cognitive deficits (most commonly a non-fluent aphasia). Some cases shown an
insidious progression that is difficult to distinguish from AD, FTD or DLB. The classical
presentation is characterized by executive dysfunction, affective dyscontrol (typically
emotional incontinence), psychomotor slowing, motor dyscontrol, parkinsonism, imbalance,
and a gait impairment (small-step, apraxic or parkinsonian gait) 34,48.
Measurement and screening for case detection
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Measurement is fundamental to neuropsychiatry practice, serving different goals – case
detection (i.e., screening), differential diagnosis, and monitoring. At present there are no
practical methods for screening for cases in the community. Proposals for screening for
dementia in primary care have typically focused on late-life cases of amnesic dementia (i.e.,
late-onset AD), and are not likely to be practical for screening for YOD – owing to the
diversity of presentations, overlap with primary affective and anxious disorders (including
major depression, bipolar disorder, and obsessive compulsive disorder), and primary
psychoses, and the variety of settings in which the cases present – primary care, psychiatry
Psychiatr Clin North Am. Author manuscript; available in PMC 2016 June 01.
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settings, and neurology clinics. Furthermore, bedside instruments such as the MMSE are not
suitable for this population because many cases – particularly those in which
neuropsychiatric phenomena define the phenotype – can attain scores matching those
attained by their counterparts who either have normal cognitive function or subclinical
impairments 49.
A practical approach to screening psychiatric populations for cases of neurodegenerative
disease involves identifying ‘red flags’ 50 – features that serve as indicators that a clinical
state may be a neurodegenerative mimic rather than a primary psychiatric state. These are
depicted in Box 1. Other aspects of measurement, pertaining to differential diagnosis and
monitoring of progression, are covered in the paper.

Conclusion
Author Manuscript

YOD are topical for psychiatry because of the syndromes, and their psychological and
psychosocial aspects, and the skillset of the psychiatrist. Psychiatrists, have a role to play in
the diagnosis of these conditions, and in their management. Understanding the clinical
epidemiology of YOD can also aid the clinician in the diagnosis of these conditions.
Appreciating the varied etiological distribution, the cognitive, neuropsychiatric, and motor
syndromes, and the clinical genetic epidemiology, allows the physician with a high index of
suspicion to apply a methodical approach to identifying potential cases, distinguishing them
from primary psychiatric conditions, and making a specific diagnosis.
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AD

Alzheimer Disease

ALS

Amyotrophic Lateral Sclerosis

ARD

Alcohol-Related Dementia

CBD

Corticobasal Degeneration

CJD

Creutzfeldt-Jakob Disease

DLB

Dementia with Lewy Bodies

FTD

Frontotemporal Dementia

FTD-ALS

FTD with Amyotrophic Lateral Sclerosis

HD

Huntington Disease

PDD

Parkinson Disease

PLA

Logopenic Progressive Aphasia

PSP

Progressive Supranuclear Palsy

SD

Semantic Dementia

TBI

Traumatic Brain Injury

VaD

Vascular Dementia
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VaD

Vascular Dementia

YOD

Young-Onset Dementia
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Box 1

Characteristics, symptoms and signs that suggest
neurodegenerative etiology of a psychiatric state
• Historical:

• Cognitive symptoms:

    – Later than typical age at onset

    – Aphasia

    – Puzzling “atypical” features

    – Apraxia

    – Family history of dementia, parkinsonism, or other
motor disorder

    – Visual complaints (other than
hallucinations)
    – Spatial disorientation

    – Unusual prodrome, e.g., insomnia, hyperphagia

    – Incontinence

    – Rapid evolution

Author Manuscript

    • Physical/motor signs
    – Abnormal posture and movement
    • Mental status:

    – Frequent falls at early stage

    – Poor insight

    – Frequent (myoclonic) jerking

    – Apathy/indifference

    – Progressive motor weakness

    – Compulsions without obsessions

    – Declining motor coordination

    – Visual hallucinations

    – Left-right asymmetry
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Key points
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1.

YOD is an important clinical and epidemiological problem that is often
overshadowed in clinical and public consciousness.

2.

Neurodegenerative diseases are the leading cause of YOD. Alzheimer disease
(AD) is most common, followed closely by frontotemporal dementia and
vascular dementia.

3.

YOD may have non-amnesic, psychiatric, and neurological presentations.

4.

An algorithmic approach interpreting clinical data, on the basis of defining
syndromes, facilitates preliminary diagnosis, and guides diagnostic testing.

5.

Screening for YOD in the psychiatric context is a rational process in which
vigilance is combined with careful searches for ‘red flags’ that signal a
psychiatric state is neurodegenerative.
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Figure 1.

Algorithm for discriminating the neurodegenerative types of young-onset dementia
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per 100,000 persons at risk

*
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INCIDENCE STUDIES
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Study/year

PREVALENCE STUDIES
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medical records
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11.5

*
Incidence

30-64

45-64

45-65

20-64

35-64

*

68.2
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55.1

42.3

54

Prevalence

6.25-19.1

11.3-15.8

8.6-15.0

Age, years
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Ikejima et al., 2009

Papageorgiou et al., 2009
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278
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N
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<65

<65

30-65

<65

Age range

*

55
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55.9

55.1

53.4

56.5

34.7

51.5

NR

NR

52.6

Age, onset

*

56.5

NR
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58.7

NR

NR

36.7

56.5

NR

58.7

56

Age, exam

*

17.7

24.2

22.3

27.2

25.6

33

1.7

17

38.8

34

27

AD

11.3

2.4

79.7

24.6

2.8

27

13.2

3

14.7

12

4

FTD

12.8

6.0

15.9

6.1

42.5

20

5.9

29

23.5

18

17

VaD

5.7

2.4

3

2.6
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4

7.7
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4.9
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4.9

1.2

5.3

4.4

6.2

4

0.4
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2.9

7.5

2

DLB/PDD

18.4

10.9

9.4
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0.4

5
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10

12

ARD

2.1
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3.8

0.87

7.1
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EX

24
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EX
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TBI

*
Age variables are in years; means are reported for age of onset and age at exam (or at ascertainment). Age range refers to the reference range for the study. Frequencies are reported as percentages of the
sample, for ease of comparison.

EX indicates that the condition was an exclusion criterion; NR indicates that the data pertaining to the variable was not reported

Some causes are not shown here (owing to our focus, limited coverage in the papers, small numbers, and space limits): dementia associated with depression (18% of cases in Ferran et al., 1996),
corticobasal degeneration, progressive supranuclear palsy, Creutzfeldt-Jakob disease, depression, cerebral tumor, multiple sclerosis, HIV infection, epilepsy, and unspecified types.

AD = Alzheimer disease, FTD = frontotemporal dementia, VaD = vascular dementia, HD= Huntington's disease, DLB = dementia with Lewy bodies, PDD = Parkinson disease dementia, ARD = alcoholrelated dementia, TBI = traumatic brain injury.
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17q21
9p13
3p11.2
4p16
20p13

MAPT
GRN
VCP
CHMP2B
Huntingtin
PRNP

Huntington disease

Prion disease

Accounts for 15% of human prion disease. Several types are recognized: fCJD, which in rare instances mimics amnesic AD, typically features
myoclonic jerks, cerebellar signs, and akinetic mutism; FFI (progressive insomnia, dysautonomia, selective thalamic degeneration); GSS (a
hereditary form with chronic cerebellar ataxia, pyramidal features, dysathria, oculodysmetria, and hyporeflexia, with dementia in later stages.

Choreoathetosis early in the course, with dystonia and akinetic rigidity in later stages. Neuropsychiatric features include executive dysfunction,
depression, irritability, impulsivity, compulsive behaviors, anger and hostility, and depression.

Very rare, seen in Danish kindred; behavioral dementia, parkinsonism and progressive spastic paresis are often seen.

Inclusion body myopathy with osteolytic bone disease (Paget's disease) and behavioral dementia.

Behavioral dementia, with aphasia, apraxia, parkinsonism, dystonia

Behavioral dementia with Parkinsonism

Behavioral dementia (FTD) with amyotrophic lateral sclerosis

Amnesic dementia associated with seizures commonly developing within 1-9 years after onset of dementia. Intracerebral hemorrhage is not
uncommon.

Very rare (typically Volga German ancestry). Most commonly presents with amnesia. There is a high degree of phenotypic variation, 33%
presenting with hallucinations and delusions, and 31% with seizures. Disease progression is slow, with rigidity, mutism and a bedridden state in the
end stages.

Often resembles sporadic AD, however behavior presentation (agitation, depression, delusions and hallucinations) and motor symptoms
(myoclonus, spastic paresis, parkinsonism, seizures are prominent in some cases.

Clinical feature

PSEN=Presenilin, APP=Amyloid precursor protein, C9ORF72 = Chromosome 9 open reading frame 72, MAPT=Microtubule-associated protein tau, GRN=Progranulin, VCP= Valosin-containing protein,
CHMP2B=Chromatin-modifying protein 2B, PRNP=prion protein; f CJD=familial CJD, FFI=Familial fatal insomnia, GSS= Gerstmann-Straussler-Sheinker Syndrome
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